{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:14:58Z","timestamp":1793225698317,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The studies that provided data for this analysis were funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s12325-018-0724-y","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T07:24:01Z","timestamp":1529047441000},"page":"1009-1022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials"],"prefix":"10.1007","volume":"35","author":[{"given":"Ralph A.","family":"DeFronzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"issue":"Suppl. 1","key":"724_CR1","first-page":"S1","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142018. Diabetes Care. 2018;41(Suppl. 1):S1\u2013159.","journal-title":"Diabetes Care"},{"key":"724_CR2","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","volume":"281","author":"RC Turner","year":"1999","unstructured":"Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005\u201312.","journal-title":"JAMA"},{"key":"724_CR3","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427\u201343.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"724_CR4","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2337\/dc09-S301","volume":"32","author":"VA Fonseca","year":"2009","unstructured":"Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S151\u20136.","journal-title":"Diabetes Care"},{"key":"724_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2337\/db09-9028","volume":"58","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773\u201395.","journal-title":"Diabetes"},{"key":"724_CR6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1185\/03007995.2011.570745","volume":"27","author":"V Hutchins","year":"2011","unstructured":"Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157\u201368.","journal-title":"Curr Med Res Opin"},{"key":"724_CR7","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/ijcp.12720","volume":"69","author":"V Woo","year":"2015","unstructured":"Woo V. Empagliflozin\/linagliptin single-tablet combination: first-in-class treatment option. Int J Clin Pract. 2015;69:1427\u201337.","journal-title":"Int J Clin Pract"},{"key":"724_CR8","doi-asserted-by":"publisher","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","volume":"309","author":"MA Abdul-Ghani","year":"2015","unstructured":"Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309:F889\u2013900.","journal-title":"Am J Physiol Renal Physiol"},{"key":"724_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78\u201389.","journal-title":"Diab Vasc Dis Res"},{"key":"724_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13:11\u201326.","journal-title":"Nat Rev Nephrol"},{"key":"724_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DMSO.S23166","volume":"6","author":"B Gallwitz","year":"2013","unstructured":"Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab Syndr Obes. 2013;6:1\u20139.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"724_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.2337\/dc14-2364","volume":"38","author":"R DeFronzo","year":"2015","unstructured":"DeFronzo R, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384\u201393.","journal-title":"Diabetes Care"},{"key":"724_CR13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2337\/dc14-2365","volume":"38","author":"A Lewin","year":"2015","unstructured":"Lewin A, DeFronzo R, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394\u2013402.","journal-title":"Diabetes Care"},{"key":"724_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"724_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1742-1241.2012.02975.x","volume":"66","author":"R Gomis","year":"2012","unstructured":"Gomis R, Owens DR, Taskinen MR, et al. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2\u00a0years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int J Clin Pract. 2012;66:731\u201340.","journal-title":"Int J Clin Pract"},{"key":"724_CR16","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.2337\/dc13-2105","volume":"37","author":"H-U H\u00e4ring","year":"2014","unstructured":"H\u00e4ring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650\u20139.","journal-title":"Diabetes Care"},{"key":"724_CR17","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/dme.12814","volume":"32","author":"L Merker","year":"2015","unstructured":"Merker L, Haering HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with type 2 diabetes. Diabet Med. 2015;32:1555\u201367.","journal-title":"Diabet Med"},{"key":"724_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","volume":"13","author":"MR Taskinen","year":"2011","unstructured":"Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65\u201374.","journal-title":"Diabetes Obes Metab"},{"key":"724_CR19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1463-1326.2012.01565.x","volume":"14","author":"G Schernthaner","year":"2012","unstructured":"Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:470\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"724_CR20","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.2337\/dc13-0663","volume":"36","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015\u201321.","journal-title":"Diabetes Care"},{"key":"724_CR21","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.clinthera.2014.06.008","volume":"36","author":"M Lehrke","year":"2014","unstructured":"Lehrke M, Marx N, Patel S, et al. Safety and tolerability of linagliptin in patients with type 2 diabetes: a comprehensive pooled analysis of 22 placebo-controlled studies. Clin Ther. 2014;36:1130\u201345.","journal-title":"Clin Ther"},{"key":"724_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","volume":"34","author":"S Kohler","year":"2017","unstructured":"Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of Phase I\u2013III clinical trials. Adv Ther. 2017;34:1707\u201326.","journal-title":"Adv Ther"},{"key":"724_CR23","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance (empagliflozin) US Prescribing Information.\u00a02017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204629s008lbl.pdf."},{"key":"724_CR24","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Glyxambi (empagliflozin and linagliptin) US Prescribing Information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206073s000lbl.pdf."},{"key":"724_CR25","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.clinthera.2016.09.001","volume":"38","author":"T Heise","year":"2016","unstructured":"Heise T, Jordan J, Wanner C, et al. Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes. Clin Ther. 2016;38:2265\u201376.","journal-title":"Clin Ther"},{"key":"724_CR26","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.clinthera.2016.08.008","volume":"38","author":"T Heise","year":"2016","unstructured":"Heise T, Jordan J, Wanner C, et al. Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus. Clin Ther. 2016;38:2248\u201364.","journal-title":"Clin Ther"},{"key":"724_CR27","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Tradjenta (linagliptin) US Prescribing Information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/201280s005lbl.pdf."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0724-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0724-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0724-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:27:59Z","timestamp":1724412479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0724-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["724"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0724-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,15]]},"assertion":[{"value":"1 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}